Guardant Health, Inc. (GH)
NASDAQ: GH · IEX Real-Time Price · USD
31.30
+0.55 (1.79%)
Jul 22, 2024, 12:36 PM EDT - Market open
Guardant Health Employees
Guardant Health had 1,779 employees as of December 31, 2023. The number of employees decreased by 14 or -0.78% compared to the previous year.
Employees
1,779
Change (1Y)
-14
Growth (1Y)
-0.78%
Revenue / Employee
$339,362
Profits / Employee
-$259,079
Market Cap
3.86B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1,779 | -14 | -0.78% |
Dec 31, 2022 | 1,793 | 420 | 30.59% |
Dec 31, 2021 | 1,373 | 509 | 58.91% |
Dec 31, 2020 | 864 | 242 | 38.91% |
Dec 31, 2019 | 622 | 168 | 37.00% |
Dec 31, 2018 | 454 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Surgery Partners | 13,500 |
Perrigo Company | 9,140 |
Sotera Health Company | 3,000 |
Waystar Holding | 1,400 |
Ultragenyx Pharmaceutical | 1,276 |
Alvotech | 1,026 |
ImmunityBio | 628 |
Axsome Therapeutics | 545 |
GH News
- 3 days ago - Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors - Business Wire
- 6 weeks ago - Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer - Business Wire
- 7 weeks ago - Guardant Health Named to TIME100 Most Influential Companies - Business Wire
- 7 weeks ago - Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening - Business Wire
- 2 months ago - FDA Advisory Committee Panel Strongly Recommends Approval of Shield™ Blood Test for Colorectal Cancer Screening as a Primary Non-Invasive Screening Option - Business Wire
- 2 months ago - U.S. FDA advisers back approval for Guardant's blood-based cancer test - Reuters
- 2 months ago - Guardant Health Stock Trading Temporarily Halted; FDA Panel to Assess Premarket Approval Application for Shield Blood Test for Colorectal Cancer Screening - Business Wire
- 2 months ago - Guardant Health to Participate in Upcoming Investor Conferences - Business Wire